Case 3-2 Amgen Whistleblowing Case
Amgen, a Thousand Oaks, California–based company, had the unenviable
task of dealing with lawsuits filed by 15 states in 2009 alleging a Medicaid
kickback scheme.1 To make matters worse, two additional whistleblowing
lawsuits were filed against the company in Ventura County. The complaints,
which don’t appear related to the fraud alleged by the group of states, were
brought by former employees who said they had uncovered wrongdoing at
the biotech giant and were terminated after they raised red flags to
superiors. One employee alleged the company violated federal law by
under-reporting complaints and problems with the company’s drugs after
they hit the market. The facts of that lawsuit are described below.
Former Amgen employee Shawn O’Brien sued Amgen for wrongful
termination on October 9, 2009, alleging he was laid off in October 2007 in
retaliation for raising concerns about how the company reported complaints
and problems with drugs already on the market. O’Brien worked as a senior
project manager for Amgen’s “Ongoing Change Program,” according to the
lawsuit filed in Ventura County Superior Court. His job was to improve
Amgen’s “compliance processes with high inherent risk to public safety,
major criminal and civil liability, or both,” according to the lawsuit.
The lawsuit alleged that in April 2007, Amgen’s board of directors flagged
the company’s process for dealing with post-market complaints about drugs
as a potential problem. Federal law requires drug companies to track and
report to the Food and Drug Administration any problems with their drugs
after they hit the market. In June 2007, O’Brien was put on the case. He
soon uncovered facts that Amgen was not adequately and consistently
identifying phone calls or mail related to post-marketing adverse events of
product complaints. That year, O’Brien warned the company about the
seriousness of the issues but, he claims, the company would not take any
action or offer any support. In August 2007, O’Brien took his complaint to a
senior executive/corporate officer (unnamed) and warned that Amgen’s
process for dealing with post-market problems wasn’t adequate.
In early September of 2007, O’Brien’s managers instructed him to stop all
work and not discuss the issues any further with anyone. Approximately
four weeks later he was informed that he was being terminated as part of
Amgen’s October 12, 2007, reduction in the work force.
To help you answer the following questions, refer to the Amgen Web site on
corporate compliance at: www.amgen.com/corporatecompliance.html.
Read the above case and write up an executive summary on the case, including
answers to the following questions.
1.
How did Amgen’s unethical behavior contribute to the problems with Medicaid
kickbacks?
2.
Why does the public consider this scandal to have an unethical dilemma?
3.
Explain what is meant by whistleblowing?
Include your opinions and identify any gaps between public expectations of ethical
standards and universal professional codes of ethical standards.
